Abstract
We would like to clarify some important issues raised in the debate about screening children with NF1-associated optic pathway glioma (OPG).1, 2 The principles of population mass screening are not applicable to the detection of OPG in young children with NF1—a significant complication in a high-risk group of patients. Ophthalmological assessments aim to detect visual impairments resulting from a symptomatic OPG rather than to identify all NF1-associated OPG, at least half of which will never cause signs or symptoms.3 Age-appropriate visual testing is recommended throughout the first decade of life to identify children requiring increased surveillance.3
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
